Technology area
In-vitro diagnostic
453 funded awards, $290.3M total, FY2023-FY2025.
Where the money sat, by Institute / Center
IC funding decisions are set by portfolio priorities, NOFO scope, and program-officer judgment. These are funded records, not predictions of future funding.
| IC | Name | Records | Median award |
|---|---|---|---|
| AI (NIAID) | National Institute of Allergy and Infectious Diseases | 182 | $847,533 |
| CA (NCI) | National Cancer Institute | 48 | $799,280 |
| GM (NIGMS) | National Institute of General Medical Sciences | 38 | $499,868 |
| HL (NHLBI) | National Heart Lung and Blood Institute | 29 | $301,224 |
| AG (NIA) | National Institute on Aging | 28 | $499,952 |
| NS (NINDS) | National Institute of Neurological Disorders and Stroke | 22 | $577,218 |
| DK (NIDDK) | National Institute of Diabetes and Digestive and Kidney Diseases | 18 | $702,486 |
| DA (NIDA) | National Institute on Drug Abuse | 15 | $803,562 |
| TR (NCATS) | National Center for Advancing Translational Sciences | 13 | $343,297 |
| HD (NICHD) | Eunice Kennedy Shriver National Institute of Child Health and Human Development | 13 | $761,233 |
| ES (NIEHS) | National Institute of Environmental Health Sciences | 8 | $276,401 |
| EY (NEI) | National Eye Institute | 8 | $753,275 |
| DE (NIDCR) | National Institute of Dental and Craniofacial Research | 6 | $313,498 |
| AR (NIAMS) | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 5 | $298,915 |
| EB (NIBIB) | National Institute of Biomedical Imaging and Bioengineering | 5 | $351,600 |
| OD | NIH Office of the Director | 5 | $301,703 |
| HG (NHGRI) | National Human Genome Research Institute | 3 | $390,584 |
| AT (NCCIH) | National Center for Complementary and Integrative Health | 3 | $920,285 |
| AA (NIAAA) | National Institute on Alcohol Abuse and Alcoholism | 3 | $272,137 |
| MH (NIMH) | National Institute of Mental Health | 1 | $950,372 |
FOA / NOFO routes
Opportunity number prefixes: PA = Parent Announcement (broad, omnibus, multiple ICs), PAR = Parent with Special Review, PAS = Parent with set-aside funds, RFA = Request for Applications (targeted, single-IC, fixed budget). Status unknown means the pipeline has not verified whether the FOA is currently posting awards; the SBIR omnibus has been in reauthorization gap during this window. See the glossary for full definitions.
| Opportunity | Status | Records |
|---|---|---|
| PA-22-176 | unknown | 131 |
| PA-21-259 | unknown | 79 |
| PA-23-230 | unknown | 78 |
| PA-24-245 | unknown | 26 |
| PA-23-232 | unknown | 18 |
| PA-21-262 | unknown | 14 |
| PA-22-178 | unknown | 13 |
| PA-24-247 | unknown | 12 |
| PAS-22-196 | unknown | 8 |
| PA-19-272 | unknown | 8 |
| PA-20-260 | unknown | 8 |
| PA-20-272 | unknown | 7 |
| PAS-22-197 | unknown | 6 |
| PAS-19-316 | unknown | 4 |
| RFA-DA-22-023 | unknown | 3 |
| RFA-CA-21-001 | unknown | 3 |
| RFA-DA-23-021 | unknown | 3 |
| PAR-24-131 | expired | 3 |
| PA-21-345 | unknown | 3 |
| PAR-22-073 | unknown | 3 |
| PA-22-177 | unknown | 2 |
| RFA-CA-23-034 | unknown | 2 |
| RFA-MD-23-003 | unknown | 2 |
| RFA-DK-21-021 | unknown | 2 |
| RFA-CA-20-033 | unknown | 2 |
| PAR-21-225 | unknown | 2 |
| PA-20-265 | unknown | 2 |
| RFA-HL-23-008 | unknown | 1 |
| PA-24-246 | unknown | 1 |
| PA-25-212 | unknown | 1 |
| PA-18-574 | unknown | 1 |
| RFA-DA-24-018 | unknown | 1 |
| RFA-MD-22-004 | unknown | 1 |
| PAR-21-247 | unknown | 1 |
| PA-20-047 | unknown | 1 |
| RFA-CA-22-025 | unknown | 1 |
Comparable funded projects
| ApplID | FY | IC | Title | Organization | Amount |
|---|---|---|---|---|---|
| 10983353 | 2025 | TR | A cross-species preclinical platform to enhance the translation of new medicines | CURI BIO INC | $1,149,771 |
| 11010813 | 2025 | AI | Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform. | TRACE-ABILITY, INC. | $1,000,000 |
| 11013882 | 2025 | AI | IND-enabling development of MM010, a PEG-specific intervention that blocks allergic response and restores repeated dosing for select PEGylated medicines impacted by anti-PEG antibody | MUCOMMUNE, LLC | $291,458 |
| 11026444 | 2025 | AI | Non-Clinical Pharmacology of CX-01 | CERAMEDIX HOLDING, LLC | $992,960 |
| 11039937 | 2025 | AI | Development of ultra-efficient antibodies for single cell mapping applications | EPICYPHER, INC. | $1,004,302 |
| 11043284 | 2025 | HL | An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-inducedThrombocytopenia | RETHAM TECHNOLOGIES, INC. | $1,154,002 |
| 11043387 | 2025 | AI | Multiplexed Assay for Point-of-Care UTI Diagnosis (ID/AMR) | NANOPATHDX, INC. | $964,943 |
| 11043396 | 2025 | HD | Automated microfluidic device for blood analysis in neonates | SERSENSE, INC. | $774,788 |
Limitations
- RePORTER includes funded projects only, not unfunded applications.
- Panel sidebar reflects panels that have appeared on funded records, not future assignment.
- FOA-route status reflects verification at the timestamp shown.
- Tag 'diagnostic_in_vitro' is a Cada controlled-vocabulary tag; see methodology for definitions.
Pattern read
In-vitro diagnostics in NIH SBIR has been overwhelmingly NIAID-driven: 182 of 453 records, or 40% of the tag, sit at NIAID. The pandemic-era investment in molecular and serological diagnostics is still visible in the dataset. NCI at 48 and NIGMS at 38 trail. Median award is $616K. The R44 share (246) outweighs R43 (145), and STTR (R41) at 45 is modest. Concentration is moderate at 7.3% across the top three orgs. The category mixes molecular diagnostics, serology, point-of-care assays, and lab-developed tests. If your assay is a software-driven interpretation layer rather than a chemistry product, the tag may surface as research_tool_or_assay or clinical_decision_support instead.
Fit indicators
Watchouts